These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 15988117

  • 1. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
    Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T.
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
    [Abstract] [Full Text] [Related]

  • 2. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
    Furuta T, Sugimoto M, Shirai N, Ishizaki T.
    Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
    [Abstract] [Full Text] [Related]

  • 3. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T.
    J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
    [Abstract] [Full Text] [Related]

  • 4. Pharmacogenomics of proton pump inhibitors.
    Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T.
    Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
    [Abstract] [Full Text] [Related]

  • 5. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E.
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [Abstract] [Full Text] [Related]

  • 6. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
    Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K.
    Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
    [Abstract] [Full Text] [Related]

  • 7. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
    Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M.
    Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y.
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [Abstract] [Full Text] [Related]

  • 9. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U.
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [Abstract] [Full Text] [Related]

  • 10. CYP2C19 genotype and the PPIs--focus on rabeprazole.
    Lim PW, Goh KL, Wong BC.
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
    [Abstract] [Full Text] [Related]

  • 11. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G.
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [Abstract] [Full Text] [Related]

  • 12. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
    Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, Droździk M.
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
    [Abstract] [Full Text] [Related]

  • 13. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
    Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T.
    Hepatogastroenterology; 2003 Jul; 50(54):2274-8. PubMed ID: 14696516
    [Abstract] [Full Text] [Related]

  • 14. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
    Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, Okumura K, Kasuga M.
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
    [Abstract] [Full Text] [Related]

  • 15. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J.
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [Abstract] [Full Text] [Related]

  • 16. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T.
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [Abstract] [Full Text] [Related]

  • 17. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
    Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH.
    Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
    Hokari K, Sugiyama T, Kato M, Saito M, Miyagishima T, Kudo M, Nishikawa K, Ishizuka J, Komatsu Y, Mizushima T, Kagaya H, Hige S, Takeda H, Asaka M.
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1479-84. PubMed ID: 11552922
    [Abstract] [Full Text] [Related]

  • 19. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
    Shirai N, Furuta T.
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():439-44. PubMed ID: 11979823
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
    Qiao HL, Hu YR, Tian X, Jia LJ, Gao N, Zhang LR, Guo YZ.
    Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.